Omeros Has Been Quietly Burning Through Cash. This Week, the Story Either Changes or It Doesn't.

Omeros Corporation (NASDAQ: OMER) reports fourth quarter and full-year 2025 results on March 30, 2026, after market close. With the biotech company expected to post another quarterly loss, investors will be focused on whether management can continue the recent trend of narrowing losses and beating expectations. The report comes as OMER trades at $9.88, well below analyst price targets that suggest significant upside potential if the company can demonstrate progress toward profitability.

Part 1: Earnings Preview

Omeros Corporation is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting inflammation, complement-mediated diseases, and disorders of the central nervous system. The company's lead products include OMIDRIA for use during cataract surgery and other intraocular lens replacement procedures.

For the fourth quarter of 2025, analysts expect Omeros to report a loss of $0.55 per share. The most recent quarter (Q3 2025) delivered a loss of $0.19 per share, representing a significant 67.24% beat versus the $0.58 loss estimate. Compared to the same quarter last year (Q4 2024), when the company reported a loss of $0.63 per share, the current estimate of -$0.55 represents meaningful year-over-year improvement of 12.70%.

Three key themes define this earnings story:

Path to Profitability: Investors are watching closely for signs that Omeros can sustain the momentum from its Q3 surprise, where losses came in significantly better than expected. The company's ability to narrow losses while managing operating expenses will be critical to demonstrating progress toward eventual profitability.

Commercial Execution: With OMIDRIA as the primary revenue driver, investors will scrutinize sales performance and market penetration metrics. Any commentary on prescription volumes, pricing dynamics, and market share gains will provide insight into the sustainability of the company's commercial trajectory.

Pipeline Development: As a biotech company still posting losses, the advancement of Omeros' clinical pipeline remains essential to the long-term investment thesis. Updates on regulatory progress, clinical trial milestones, and potential new product launches will be closely monitored for their impact on future revenue potential and the timeline to profitability.

Part 2: Historical Earnings Performance

Omeros has demonstrated improving execution against analyst expectations over the past two quarters. In Q2 2025 (June), the company posted a loss of $0.53 per share against an estimate of -$0.55, delivering a modest 3.64% beat. The momentum accelerated dramatically in Q3 2025 (September), when the company reported a loss of just $0.19 per share versus the -$0.58 estimate, representing a substantial 67.24% beat that significantly exceeded expectations.

This recent performance marks a notable shift from earlier quarters when analyst estimates were unavailable, making it difficult to assess performance against expectations. The year-over-year trend also shows improvement: comparing Q4 2024's actual loss of $0.63 per share to the current Q4 2025 estimate of -$0.55 reflects a 12.70% improvement, suggesting the company is making tangible progress in narrowing its losses.

The pattern suggests building operational momentum, with the company not only meeting but substantially exceeding expectations in its most recent report. If Omeros can deliver another beat in the upcoming Q4 release, it would establish a clear trend of outperformance that could boost investor confidence in management's ability to execute on its path toward profitability.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Omeros reports after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual earnings data.

Omeros exhibits exceptionally high volatility around earnings releases, with an average absolute Day +1 move of 18.93% — nearly five times the typical Day 0 move of 3.84%. The most dramatic example came in November 2024, when the stock surged 65.87% the day after earnings, followed by the most recent November 2025 report that saw an 8.85% decline on Day 0 but a powerful 25.32% rally on Day +1.

The pattern is clear: the real price action happens after results are digested, not in anticipation. Day +1 ranges average 23.27% compared to just 7.67% on Day 0, indicating that investors wait for the actual numbers before making significant positioning decisions. The directional bias has been mixed, with four positive and four negative Day +1 moves over the past eight quarters, but the magnitude of moves in both directions has been substantial — including declines of 18.61% and 20.62% in May 2025 and May 2024, respectively. Investors should prepare for significant volatility in the session following the March 30 after-hours release.

Part 2.2: Options Market Expected Move

The options market is pricing a 14.14% expected move (±$1.40, establishing a range of $8.52 to $11.32) for the April 17 expiration, which is notably lower than the stock's historical average Day +1 move of 18.93%. This suggests options traders may be underpricing the potential volatility, given Omeros' track record of delivering moves exceeding 20% in four of the past eight earnings releases.

Part 3: What Analysts Are Saying

Analysts maintain a bullish stance on Omeros with an average rating of 4.00 (Buy) and a mean price target of $43.67, implying substantial 342% upside from the current price of $9.88. The consensus is supported by 3 Strong Buy ratings and 3 Hold ratings, with no sell recommendations among the 6 analysts covering the stock. Price targets range from a low of $36.00 to a high of $55.00, with even the most conservative estimate suggesting significant appreciation potential.

Analyst sentiment has remained unchanged over the past month, with the rating distribution and average recommendation holding steady at 4.00. This stability suggests analysts are maintaining conviction in their bullish thesis despite recent price weakness. The wide gap between the current trading price and the consensus target reflects analyst confidence that Omeros' commercial execution and pipeline development will eventually drive substantial value creation, though the timeline for realizing that upside remains dependent on the company's ability to demonstrate sustained progress toward profitability and successful advancement of its clinical programs.

Part 4: Technical Picture

The Barchart Technical Opinion currently shows a 24% Buy signal, representing a significant deterioration from 40% Buy one week ago and 40% Buy one month ago. This weakening technical picture reflects recent downward pressure as the stock has pulled back from higher levels.

Timeframe Analysis:

• Short-term (Hold): Neutral signal indicates near-term momentum has stalled, suggesting consolidation or indecision in the immediate trading environment
• Medium-term (50% Buy): Moderate buy signal suggests the intermediate trend retains some positive bias despite recent weakness
• Long-term (50% Buy): Moderate buy signal reflects a constructive longer-term trend, though not at full strength

Trend Characteristics: The trend is characterized as Weak and Weakening, indicating deteriorating momentum heading into the earnings release and suggesting caution for traders looking to establish new positions before the report.

The stock is trading below all key short- and intermediate-term moving averages — sitting below the 5-day ($10.29), 10-day ($10.69), 20-day ($11.14), 50-day ($11.49), and 100-day ($11.00) averages. However, OMER remains above the 200-day moving average of $7.73, indicating the longer-term uptrend from lower levels remains intact despite recent weakness. The current price of $9.88 represents a 14% decline from the 50-day average, suggesting the stock has experienced meaningful technical deterioration. With resistance now stacked overhead at multiple moving average levels and momentum indicators weakening, the technical setup is cautionary heading into earnings. Bulls will need to see a strong fundamental catalyst from the March 30 report to reverse the recent downtrend and reclaim key technical levels.